The Urologic Oncology Program follows a team approach to diagnosing and treating those with prostate cancer. Our patients have their situation discussed not only by our urologic oncologists and surgeons, but also by experts in radiation oncology and pathology. By having everyone involved, a personalized treatment plan is developed. All of this takes place in our Multidisciplinary Urologic Oncology Clinic.
In addition, we recognize the important needs of men diagnosed with high-risk or advanced cancer and offer advanced cancer care, individual genetic analysis and precise treatment.
The Urologic Oncology Program is the recipient of a $6.5 million Specialized Program of Research Excellence grant in prostate cancer, a George M. O’Brien Urology Research Center grant, a PO1 in prostate cancer metastasis to bone, and two T32 Urology Training Grants. Active laboratory programs include work in the areas of prostate cancer genetics, gene discovery, metastasis, biomarker discovery, therapeutic development, and prostate and bladder cell biology. Recently, research has expanded broadly into specific evaluation of quality-of-life outcomes analyses for localized and metastatic bladder and prostate cancers. Clinical trials involving gene therapy, chemotherapy, immunotherapy and targeted agents are available for prostate, bladder and renal-cell cancers.